The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2020 | Novel targeted therapies for CLL
Othman Al-Sawaf, MD, of the University Hospital of Cologne, Cologne, Germany, explores novel, targeted therapies for chronic lymphocytic leukemia (CLL), including second-generation BTK inhibitors, CD20 targeting antibodies, CAR T-cell therapy as well as the importance of combination approaches. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
